BioSpace News Archive

Cloud DX a leading Canadian provider of virtual care and remote patient monitoring solutions is pleased to announce that, subject to regulatory approval, it has retained Red Cloud Securities to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2021

Project Health to provide free health screenings in 14 new metro markets and launch four mobile units in 2021 to increase program’s reach to areas of significant need

Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET,

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to the same period in 2020.

Sales revenues amounted to € 219.6 million, in line with the previous year; EBITDA increased by 34%, reaching € 34 million.

Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of optical sensors for non-invasive, real-time monitoring of cell culture systems through its subsidiary Scientific Bioprocessing, Inc. (“SBI”), today announced its acquisition of aquila biolabs GmbH,

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access to its accelerated solutions platform, spanning research & development to manufacturing for orphan and rare disease products.

Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that on April 26, 2021 the company entered negotiations and formed an action plan with the Matam Technopark in Haifa, Israel to pursue joint development, acquisition and adaptation of pharmaceutical technologies.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that it will participate in the following upcoming virtual conferences